Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. (öffnet neues Fenster)

CRASH-3 Trial Collaborators

Quelle‎: Lancet 2019;394(10210):1713-23.

Indiziert‎: PubMed 31623894

DOI‎: 10.1016/S0140-6736(19)32233-0

https://www.ncbi.nlm.nih.gov/pubmed/31623894 (öffnet neues Fenster)

Alternatives to allogeneic platelet transfusion. (öffnet neues Fenster)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Quelle‎: Br J Haematol 2016;175(3):381-92.

Indiziert‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (öffnet neues Fenster)

Tranexamic acid: less bleeding and less thrombosis? (öffnet neues Fenster)

Godier A, Roberts I, Hunt BJ.

Quelle‎: Crit Care 2012;16(3):135.

Indiziert‎: PubMed 22748073

DOI‎: 10.1186/cc11374

https://www.ncbi.nlm.nih.gov/pubmed/22748073 (öffnet neues Fenster)

Tranexamic acid for reducing mortality in emergency and urgent surgery. (öffnet neues Fenster)

Perel P, Ker K, Morales Uribe CH, Roberts I

Quelle‎: Cochrane Database Syst Rev 2013;(1):CD010245.

Indiziert‎: PubMed 23440847

DOI‎: 10.1002/14651858.CD010245.pub2

https://www.ncbi.nlm.nih.gov/pubmed/23440847 (öffnet neues Fenster)

The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. (öffnet neues Fenster)

Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T; CRASH-2 collaborators.

Quelle‎: Lancet 2011;377(9771):1096-101, 1101.e1-2.

Indiziert‎: PubMed 21439633

DOI‎: 10.1016/S0140-6736(11)60278-X

https://www.ncbi.nlm.nih.gov/pubmed/21439633 (öffnet neues Fenster)

Antifibrinolytic drugs for acute traumatic injury. (öffnet neues Fenster)

Roberts I, Shakur H, Ker K, Coats T; CRASH‐2 Trial collaborators.

Quelle‎: Cochrane Database Syst Rev 2011;(1):CD004896.

Indiziert‎: PubMed 21249666

DOI‎: 10.1002/14651858.CD004896.pub3

https://www.ncbi.nlm.nih.gov/pubmed/21249666 (öffnet neues Fenster)

Use of tranexamic acid to reduce bleeding in burns surgery. (öffnet neues Fenster)

Tang YM, Chapman TW, Brooks P

Quelle‎: J Plast Reconstr Aesthet Surg 2012;65(5):684-6.

Indiziert‎: PubMed 21983540

DOI‎: 10.1016/j.bjps.2011.09.028

https://www.ncbi.nlm.nih.gov/pubmed/21983540 (öffnet neues Fenster)

Tranexamic acid reduced blood transfusions in acute burn surgery: a retrospective case-controlled trial. (öffnet neues Fenster)

Tapking C, Hundeshagen G, Kirchner M, Fischer S, Kneser U, Bliesener B

Quelle‎: Burns. 2022;48(3):522-28.

Indiziert‎: PubMed 35339324

DOI‎: 10.1016/j.burns.2022.03.002

https://pubmed.ncbi.nlm.nih.gov/35339324/ (öffnet neues Fenster)

Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery. (öffnet neues Fenster)

Barua A, Rao VP, Ramesh B, Barua B, El-Shafei H.

Quelle‎: J Blood Med 2011;2:131-4.

Indiziert‎: PubMed 22287872

DOI‎: 10.2147/JBM.S21609

https://www.ncbi.nlm.nih.gov/pubmed/22287872 (öffnet neues Fenster)

The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. (öffnet neues Fenster)

Boffard KD, Choong PI, Kluger Y, Riou B, Rizoli SB, Rossaint R, Warren B; NovoSeven Trauma Study Group.

Quelle‎: Transfusion 2009;49 Suppl 5:240S-7S.

Indiziert‎: PubMed 19954486

DOI‎: 10.1111/j.1537-2995.2008.01987.x

https://www.ncbi.nlm.nih.gov/pubmed/19954486 (öffnet neues Fenster)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (öffnet neues Fenster)

Fries D

Quelle‎: Transfusion 2013;53 Suppl 1:91S-5S.

Indiziert‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (öffnet neues Fenster)

A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature. (öffnet neues Fenster)

Haan J, Scalea T

Quelle‎: Am Surg 2005;71(5):414-5.

Indiziert‎: PubMed 15986972

https://www.ncbi.nlm.nih.gov/pubmed/15986972 (öffnet neues Fenster)

Results of the control trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. (öffnet neues Fenster)

Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, Leppaniemi A, Parr M, Vincent JL, Tortella BJ, Dimsits J, Bouillon B; CONTROL Study Group.

Quelle‎: J Trauma 2010;69(3):489-500.

Indiziert‎: PubMed 20838118

DOI‎: 10.1097/TA.0b013e3181edf36e

https://www.ncbi.nlm.nih.gov/pubmed/20838118 (öffnet neues Fenster)

Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. (öffnet neues Fenster)

Hsia CC, Chin-Yee IH, McAlister VC.

Quelle‎: Ann Surg 2008;248(1):61-8.

Indiziert‎: PubMed 18580208

DOI‎: 10.1097/SLA.0b013e318176c4ec

https://www.ncbi.nlm.nih.gov/pubmed/18580208 (öffnet neues Fenster)

Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases. (öffnet neues Fenster)

Johansson PI, Eriksen K, Alsbjørn B

Quelle‎: J Trauma 2006;61(4):1016-8.

Indiziert‎: PubMed 17033583

DOI‎: 10.1097/01.ta.0000239261.48022.f1

https://www.ncbi.nlm.nih.gov/pubmed/17033583 (öffnet neues Fenster)

Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding. (öffnet neues Fenster)

Kandane-Rathnayake RK, Isbister JP, Zatta AJ, Aoki NJ, Cameron P, Phillips LE; Australian and New Zealand Haemostasis Registry Steering Committee

Quelle‎: ANZ J Surg 2013;83(3):155-60.

Indiziert‎: PubMed 23035873

DOI‎: 10.1111/j.1445-2197.2012.06285.x

https://www.ncbi.nlm.nih.gov/pubmed/23035873 (öffnet neues Fenster)

Recombinant factor VIIa in trauma patients with the 'triad of death.' (öffnet neues Fenster)

Mitra B, Cameron PA, Parr MJ, Phillips L.

Quelle‎: Injury 2012;43(9):1409-14.

Indiziert‎: PubMed 21345431

DOI‎: 10.1016/j.injury.2011.01.033

https://www.ncbi.nlm.nih.gov/pubmed/21345431 (öffnet neues Fenster)

Low-dose recombinant factor VIIa for trauma patients with coagulopathy. (öffnet neues Fenster)

Stein DM, Dutton RP, Hess JR, Scalea TM.

Quelle‎: Injury 2008;39(9):1054-61.

Indiziert‎: PubMed 18656871

DOI‎: 10.1016/j.injury.2008.03.032

https://www.ncbi.nlm.nih.gov/pubmed/18656871 (öffnet neues Fenster)

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven®). (öffnet neues Fenster)

Tanaka KA, Waly AA, Cooper WA, Levy JH.

Quelle‎: Anesthesiology 2003;98(6):1513-5.

Indiziert‎: PubMed 12766668

https://www.ncbi.nlm.nih.gov/pubmed/12766668 (öffnet neues Fenster)

Alternatives to allogeneic platelet transfusion. (öffnet neues Fenster)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Quelle‎: Br J Haematol 2016;175(3):381-92.

Indiziert‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (öffnet neues Fenster)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (öffnet neues Fenster)

Fries D

Quelle‎: Transfusion 2013;53 Suppl 1:91S-5S.

Indiziert‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (öffnet neues Fenster)

Plasma fibrinogen level on admission to the intensive care unit is a powerful predictor of postoperative bleeding after cardiac surgery with cardiopulmonary bypass. (öffnet neues Fenster)

Kindo M, Hoang Minh T, Gerelli S, Perrier S, Meyer N, Schaeffer M, Bentz J, Announe T, Mommerot A, Collange O, Pottecher J, Cristinar M, Thiranos JC, Gros H, Mertes PM, Billaud P, Mazzucotelli JP

Quelle‎: Thromb Res 2014;134(2):360-8.

Indiziert‎: PubMed 24857189

DOI‎: 10.1016/j.thromres.2014.05.008

https://www.ncbi.nlm.nih.gov/pubmed/24857189 (öffnet neues Fenster)

Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. (öffnet neues Fenster)

Larsen OH, Stentoft J, Radia D, Ingerslev J, Sørensen B

Quelle‎: Br J Haematol 2013;160(2):228-36.

Indiziert‎: PubMed 23151086

DOI‎: 10.1111/bjh.12118

https://www.ncbi.nlm.nih.gov/pubmed/23151086 (öffnet neues Fenster)

Strategies to reduce the use of blood products: a European perspective. (öffnet neues Fenster)

Theusinger OM, Felix C, Spahn DR.

Quelle‎: Curr Opin Anaesthesiol 2012;25(1):59-65.

Indiziert‎: PubMed 22113184

DOI‎: 10.1097/ACO.0b013e32834dec98

https://www.ncbi.nlm.nih.gov/pubmed/22113184 (öffnet neues Fenster)

Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. (öffnet neues Fenster)

Crescenzi G, Landoni G, Biondi-Zoccai G, Pappalardo F, Nuzzi M, Bignami E, Fochi O, Maj G, Calabrò MG, Ranucci M, Zangrillo A

Quelle‎: Anesthesiology 2008;109(6):1063-76.

Indiziert‎: PubMed 19034103

DOI‎: 10.1097/ALN.0b013e31818db18b

https://www.ncbi.nlm.nih.gov/pubmed/19034103 (öffnet neues Fenster)

Alternatives to allogeneic platelet transfusion. (öffnet neues Fenster)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Quelle‎: Br J Haematol 2016;175(3):381-92.

Indiziert‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (öffnet neues Fenster)

Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. (öffnet neues Fenster)

Svensson PJ, Bergqvist PB, Juul KV, Berntorp E

Quelle‎: Blood Rev 2014;28(3):95-102.

Indiziert‎: PubMed 24703870

DOI‎: 10.1016/j.blre.2014.03.001

https://www.ncbi.nlm.nih.gov/pubmed/24703870 (öffnet neues Fenster)

Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. (öffnet neues Fenster)

Alperin JB

Quelle‎: JAMA 1987;258(14):1916-9.

Indiziert‎: PubMed 3656602

DOI‎: 10.1001/jama.1987.03400140078028

https://www.ncbi.nlm.nih.gov/pubmed/3656602 (öffnet neues Fenster)

Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. (öffnet neues Fenster)

Crowther MA, McDonald E, Johnston M, Cook D

Quelle‎: Blood Coagul Fibrinolysis 2002;13(1):49-52.

Indiziert‎: PubMed 11994567

DOI‎: 10.1097/00001721-200201000-00007

https://www.ncbi.nlm.nih.gov/pubmed/11994567 (öffnet neues Fenster)

The use of fibrin sealant in burn operations. (öffnet neues Fenster)

Foster K

Quelle‎: Surgery 2007;142(4 Suppl):S50-4.

Indiziert‎: PubMed 18019939

DOI‎: 10.1016/j.surg.2007.06.026

https://www.ncbi.nlm.nih.gov/pubmed/18019939 (öffnet neues Fenster)

Use of fibrin sealant in thermal injury. (öffnet neues Fenster)

McGill V, Kowal-Vern A, Lee M, Greenhalgh D, Gomperts E, Bray G, Gamelli R

Quelle‎: J Burn Care Rehabil 1997;18(5):429-34.

Indiziert‎: PubMed 9313125

DOI‎: 10.1097/00004630-199709000-00011

https://www.ncbi.nlm.nih.gov/pubmed/9313125 (öffnet neues Fenster)

Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements. (öffnet neues Fenster)

Schaden E, Kimberger O, Kraincuk P, Baron DM, Metnitz PG, Kozek-Langenecker S

Quelle‎: Br J Anaesth 2012;109(3):376-81.

Indiziert‎: PubMed 22719014

DOI‎: 10.1093/bja/aes186

https://www.ncbi.nlm.nih.gov/pubmed/22719014 (öffnet neues Fenster)

Transfusion in trauma: why and how should we change our current practice? (öffnet neues Fenster)

Theusinger OM, Spahn DR, Ganter MT.

Quelle‎: Curr Opin Anaesthesiol 2009;22(2):305-12.

Indiziert‎: PubMed 19390257

DOI‎: 10.1097/ACO.0b013e3283212c7c

https://www.ncbi.nlm.nih.gov/pubmed/19390257 (öffnet neues Fenster)

Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. (öffnet neues Fenster)

Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens J, Kleijnen J

Quelle‎: Health Technol Assess 2015;19(58):1-228.

Indiziert‎: PubMed 26215747

DOI‎: 10.3310/hta19580

https://www.ncbi.nlm.nih.gov/pubmed/26215747 (öffnet neues Fenster)